Comparative AAV-eGFP Transgene Expression Using Vector Serotypes 1–9, 7m8, and 8b in Human Pluripotent Stem Cells, RPEs, and Human and Rat Cortical Neurons
Open Access
- 17 January 2019
- journal article
- research article
- Published by Wiley in Stem Cells International
- Vol. 2019, 1-11
Abstract
Recombinant adeno-associated virus (rAAV), produced from a nonpathogenic parvovirus, has become an increasing popular vector for gene therapy applications in human clinical trials. However, transduction and transgene expression of rAAVs can differ acrossin vitroand ex vivo cellular transduction strategies. This study compared 11 rAAV serotypes, carrying one reporter transgene cassette containing a cytomegalovirus immediate-early enhancer (eCMV) and chicken beta actin (CBA) promoter driving the expression of an enhanced green-fluorescent protein (eGFP) gene, which was transduced into four different cell types: human iPSC, iPSC-derived RPE, iPSC-derived cortical, and dissociated embryonic day 18 rat cortical neurons. Each cell type was exposed to three multiplicity of infections (MOI: 1E4, 1E5, and 1E6 vg/cell). After 24, 48, 72, and 96 h posttransduction, GFP-expressing cells were examined and compared across dosage, time, and cell type. Retinal pigmented epithelium showed highest AAV-eGFP expression and iPSC cortical the lowest. At an MOI of 1E6 vg/cell, all serotypes show measurable levels of AAV-eGFP expression; moreover, AAV7m8 and AAV6 perform best across MOI and cell type. We conclude that serotype tropism is not only capsid dependent but also cell type plays a significant role in transgene expression dynamics.Keywords
Funding Information
- Paul MacKall and Evanina Bell MacKall Trust (P30EY01583-26, IK2RX002013)
- National Institutes of Health (P30EY01583-26, IK2RX002013)
- F. M. Kirby Foundation (P30EY01583-26, IK2RX002013)
- Research to Prevent Blindness (P30EY01583-26, IK2RX002013)
- Robert and Susan Heidenberg Investigative Research Fund for Ocular Gene Therapy (P30EY01583-26, IK2RX002013)
- Department of Veterans Affairs (P30EY01583-26, IK2RX002013)
- Foundation for Fighting Blindness (P30EY01583-26, IK2RX002013)
- Center for Advanced Retinal and Ocular Therapeutics (P30EY01583-26, IK2RX002013)
- Vietnam Education Fund (P30EY01583-26, IK2RX002013)
This publication has 40 references indexed in Scilit:
- Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal EffectsPLOS ONE, 2013
- AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized ModelsPLOS ONE, 2013
- Pyramidal Neurons Derived from Human Pluripotent Stem Cells Integrate Efficiently into Mouse Brain Circuits In VivoNeuron, 2013
- Elucidating the phenomenon of HESC-derived RPE: Anatomy of cell genesis, expansion and retinal transplantationExperimental Neurology, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicityBrain Research, 2008
- Comparative analysis of in vivo and in vitro AAV vector transduction in the neonatal mouse retina: Effects of serotype and site of administrationVision Research, 2007
- Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1Journal of Virology, 2003
- Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virusVision Research, 2002
- Enhancement of Muscle Gene Delivery with Pseudotyped Adeno-Associated Virus Type 5 Correlates with Myoblast DifferentiationJournal of Virology, 2001